New eye injection PRO-169 enters safety trial for Diabetes-Related vision loss
NCT ID NCT07429474
First seen Feb 26, 2026 · Last updated Jun 19, 2026 · Updated 11 times
Summary
This Phase 1 trial will test the safety of PRO-169, a form of bevacizumab injected into the eye, in 60 adults with diabetic macular edema. The study checks for immune reactions and side effects. It is not yet recruiting and focuses on safety, not whether it improves vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asociación para Evitar la Ceguera en México I.A.P
Coyoacán, Mexico City, 04030, Mexico
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (PRO-169)
What this could lead to
If successful, this could show that PRO-169 is safe and may lead to a new treatment option for diabetic macular edema.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so results may not apply broadly. The main focus is safety, not effectiveness, and there is a risk of immune reactions or other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.